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Discovery and Development of Insulin 
Insulin is an anabolic polypeptide hormone secreted by the beta 
cells of the pancreatic islets of Langerhans. Before the discovery of 
insulin, scientists used various extracts from the pancreas to lower 
blood glucose in laboratory animals. However it was re-infusion of 
a pancreatic extract into a pancreatectomised dog that improved 
hyperglycemia. This discovery led to the development of a procedure 
for beef pancreas extract and in 1923, Lilly® patented Iletin (mixed 
porcine/bovine isophane). This was followed in 1926 with the isolation 
of crystalline insulin and the unravelling of the sequence and structure 
of insulin in 1956 (Figure 1). 
Zinc and a low molecular weight protein called protamine were 
subsequently developed and isophane neutral Hagedorn (NPH) 
insulin, bound to protamine, became available. Long acting insulins 
such as semilente, lente and ultra- lente were developed. However 
antibody allergies and lipoatrophy started to be noticed due to the 
antigenicity from the porcine and bovine proteins.
In 1975 human insulin was synthesized which was timely as by then 
Lilly® was using 1 ton of pancreas per hour to make enough insulin. 
Within 3 years a genetically manipulated plasmid of E. coli bacteria 
was used to individually express the A and B insulin chain and thus 
successfully produce recombinant human insulin. This breakthrough 
provided the first opportunity to mass-produce ‘human’ insulin 
using gene technology resulting in recombinant Humulin R (rapid), 
Humulin N (NPH) and the semi-synthetic insulins Actrapid and 
Monotard. It also offered the opportunity to manipulate the insulin 
sequence enabling development of genetically modified insulins to 
improve the pharmacokinetic profile. Currently a large number of 
additional analogue insulin formulae are being tested. 
Specific Analogues
Absorption and Distribution
Prandial insulin: A) Regular Human Insulin (RHI): When zinc 
atoms are added to human insulin in solution, insulin monomers self 
associate to form hexameric insulin. These larger hexamers are slowly 
absorbed and then slowly dissociate into dimers and monomers that 
then diffuse into the circulation more rapidly, but with similar total 
absorption. After subcutaneous injection, RHI concentrations peak 
at 1-2 hours and return to baseline after 6-8 hours. However there 
is great variability, with up to 15-25% variability in intra- and inter-
individual concentrations. This is due to a number of factors including 
dose, re-suspension technique, site, amount of subcutaneous adipose 
tissue (with less fat increasing absorption) and blood flow [1,2]. The 
desire to both mimic endogenous meal related insulin secretion more 
closely and to improve the consistency of absorption and distribution 
kinetics, encouraged the development and subsequent identification 
of molecular modifications to reduce hexamer formation and improve 
absorption. These modifications have underpinned the development of 
the “new” synthetic insulins. 
B) Rapid acting analogues (Aspart [AspB28 human insulin], 
Abstract
The issue of planning the timing and dosing of insulin in relation to food is one of the most difficult issues 
confronting people with diabetes. Recent focus on improving quality of life in this area has focused on developing 
different modes of administration of insulin thereby avoiding subcutaneous injections and developing new analogues 
of insulin. Both inhalational and buccal administration technologies have been developed, and have essentially 
overcome some of the difficult pharmacokinetic issues regarding large peptide molecules, however there remain 
some clinical problems. Advances in the practicalities of treating insulin have occurred, such as more accurate and 
less expensive glucometers, new administration alternatives such as implantable pumps, with further developments 
in the pipeline including islet and gene replacement for Type I disease. However all of these newer options have 
limitations and currently subcutaneous administration is the only real option for most people. Insulin analogues have 
so far been relatively disappointing in terms of improvement in mortality and morbidity although for some patients 
the ability to alter the dosage of insulin depending on the planned meal size or reduction of between meal snacks 
has been helpful. Furthermore there is a yet unknown question around long term safety. This review will discuss the 
major clinical issues surrounding the new insulin analogues as they relate to efficacy and side effects.
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Lispro [28(B)-L-lysine-29(B)-L-proline-human insulin], Glulisine 
[3(B)-Lys, 29(B)-Glu-human insulin]): These synthetic insulin 
analogues have molecular modifications that delay self association of 
insulin monomers, enabling more rapid absorption of injected drug 
and more rapid attainment of maximum concentrations. This leads 
to closer replication of the normal prandial insulin response when 
compared to RHI [3]. Insulin lispro, aspart, and glulisine have nearly 
identical pharmacology profiles [4] and may have less intra- and inter-
individual variation in absorption than human insulin [3]. The peak 
activity of rapid acting analogues is at about 1 hour and duration of 
action is approximately 3-4 hours [5]. Glulisine formulation, unlike 
the other analogues, does not have added hexamer-producing zinc. 
This may have benefits in the absorption, although this has so far not 
translated into any measurable benefit in diabetes control or side effects 
profile.
Basal insulin:
A) Neutral Protamine Hagedorn (NPH): NPH has peak activity 
at 4-6 hours post injection and total duration of action of 12-16 hours.
B) Glargine [Gly A21, Arg B31, Arg B32] insulin: The molecular 
modifications made to insulin glargine ensure that it is soluble at acidic 
pH (resulting in a clear insulin in the vial) with less solubility at neutral 
pH resulting in a micro-precipitate at the injection site. This effect delays 
absorption from the subcutaneous site resulting in a delayed onset of 
action (1.5 vs. 0.8 hours for NPH), flatter (but not “flat”) absorption 
profile and a prolonged duration of action (10-26 vs. 14 hours) [6]. 
Recently it has been noted that up to 33% of adult patients with T1DM 
appear to require twice rather than once daily dosing of glargine.
C) Detemir [LysB29(Nε-tetradecanoyl) des(B30) human 
insulin]: The addition of the fatty acid side chain in detemir allows 
the molecule to bind reversibly to albumin with high affinity in the 
subcutaneous, intravascular and extracellular compartments. This 
slows both absorption and excretion however twice daily dosing is still 
often required. The fatty acid side-chain enhances self-association of 
monomers in the subcutaneous depot, which as well as contributing to 
prolongation of action reduces variability of the time effect profile [7].
Clearance
Prandial insulin: Hepatic clearance is the major site of metabolism 
for circulating insulin although approximately 30% of systemically 
circulating insulin is renally cleared with a small amount of degradation 
by circulation proteases. The renal clearance is theoretically an issue for 
people with impaired renal function, with reduced insulin requirements 
sometimes but not always required as renal function decreases, 
perhaps due to other insulin degradation pathways including greater 
endocytosis-lysosomal and enzymatic degradation in proximal tubular 
cells [8]. 
Insulin aspart pharmacokinetics are not affected in a clinically 
Figure 1: Structures of new insulins. This Figure has been reproduced from Nature Reviews Drug Discovery 1, 529-540 (July 2002) New horizons — alternative routes 
for insulin therapy by David R. Owens (with permission)
· The newer insulins have greater similarity to each other than to the older 
insulins
· The newer short acing insulins may enable more flexibility with dosing 
regimens, meal composition and requirement for between meal snacks 
than older insulins
· Both detemir and glargine may need to be used in a twice daily regimen 
to enable control of HbA1c
· Detemir may have weight advantages over older insulins in obese people 
with type 2 diabetes
· Older insulins have a wealth of safety data and as yet the mitogenic 
potential of the new insulins, especially over a lifetime is not fully known
· Newer insulins do not provide any efficacy advantage (in terms of HbA1c) 
but do offer convenience and may provide a reduction (but not elimination) 
of nocturnal hypoglycaemia
Table 1: Summary Points.
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significant manner by liver disease, mild-moderate renal impairment 
or BMI [9]. Glulisine does not appear to accumulate in patients with 
renal impairment [10].
Basal insulin:
A) Glargine: Glargine is a pro-drug which undergoes partial rapid 
clearance at the injection site by metabolism to two active metabolites 
M1 and M2, the remainder of which is metabolized by plasma 
peptidases in the circulation [11]. 
B) Detemir: The molecular modifications present in detemir 
(removal of threonine at position B30 and the acylation of a 14-carbon 
myristoyl fatty acid to lysine at position B29) enable tight but 
reversible binding to albumin, reducing hepatic clearance. Neither 
hepatic nor renal impairment exert a clinically relevant effect on the 
pharmacokinetic profile of detemir [12].
Dose Response
Prandial insulin: Insulin glulisine is the newest human insulin 
analogue product for the control of prandial blood glucose. As with 
aspart and lispro, glulisine displays faster absorption and onset of 
action, with a shorter duration of action than that of RHI [13]. 
The duration of action of lispro, aspart and glulisine only modestly 
increase with higher doses [2,10] however with increasing doses of 
RHI both the duration of action and the maximal metabolic response 
increase.
Basal insulin:
A) Glargine: A recent meta-analysis of insulin analogues showed 
that the duration of action for both insulin detemir and insulin glargine 
displayed dose dependency, with an average 24 hour duration of action 
in a clinically relevant dosing range of 0.35 U/kg to 0.8 U/kg in patients 
with type 1 diabetes [14]. Similar findings have been seen in type 2 
patients [15], however clinically BD dosing is used for both.
B) Detemir: Data in healthy subjects show that insulin detemir has 
a flatter time-action profile than NPH, reaching its peak concentration 
nearly 90 min later [16].
Receptor Affinity, Signaling and Mitogenicity
Upon binding the insulin receptor (IR) or insulin-like growth factor 
1 receptor (IGF-1R) autophosphorylation and downstream  signalling 
cascades ensue. In very simple terms, insulin can signal via the IR to 
“metabolic” pathways (via IRS-1/PI3K/AKT) or “mitogenic” pathways 
(via MAP kinase). “Metabolic” responses include glucose uptake, 
suppression of gluconeogenesis and anabolism. “Mitogenic” effects 
include cell proliferation and anti-apoptosis. IGF-1R signalling is 
predominately “mitogenic”.
The net “mitogenic” vs “metabolic” effect of insulin and its analogues 
is determined by cellular expression of IR, IGF-1R and hybrid receptors, 
insulin concentration (higher concentrations favour mitogenic 
signalling) and insulin sequence. This is of therapeutic relevance 
because numerous insulin analogues, including inhaled insulins 
such as Exubera® (which require high dosages) have not proceeded 
to clinical trial because of a number of factors including cost and 
acceptability but also due to concerns regarding mitogenic effects [17]. 
In vitro studies for example have shown that particular modifications 
to the insulin molecule can alter affinity for the insulin and IGF-1 
receptor and receptor occupancy time, and that these alterations can 
affect mitogenic potential [18]. Analogues with reduced dissociation 
time (i.e. longer receptor occupancy) have a disproportionate increase 
in mitogenic activity compared to metabolic activity. Specifically, 
insulin glargine was found to have a six to eight fold increase in IGF-1 
receptor affinity and mitogenic potency compared with human insulin. 
Glargine metabolites show mitogenicity but less than the parent [11]. 
Rodent in vivo studies have not shown any increase in carcinogenicity 
with glargine however [19]. 
Insulin aspart and lispro appear to be similar to human insulin 
in metabolic potency and insulin receptor affinity although lispro has 
been noted to have a 1.5 fold higher IGF-1 receptor affinity compared 
to human insulin [20]. However mitogenic potential was not altered 
compared to aspart or regular human insulin. In a mammary cell line 
only glargine of the insulin analogues showed a significantly higher 
proliferative effect on MCF 7 breast cancer cells [21]. More recently 
studies of glulisine suggest that this agent has similar insulin receptor 
association, dissociation, affinity kinetics and similar mitogenic and 
metabolic potency to RHI [22].
Detemir, as a consequence of its fatty acyl chain, has a lower affinity 
for the insulin receptor [7]. However it dissociates from the insulin 
receptor 2-fold faster and is associated with reduced mitogenic potency 
compared to human insulin [7]. 
The clinical and long-term implications of these in vitro studies 
are not fully known. However since 2008 when an observational study 
on inhaled insulin analogues was associated with six new cases of lung 
cancer in smokers/ex-smokers as opposed to one in the comparator 
arm [23] there have been concerns regarding the use of insulin 
analogues and cancer. A prospective observational study in Sweden 
from 2006-7 has shown an adjusted increased risk of breast cancers in 
users of monotherapy glargine as compared to other types of insulin 
(RR 1.97, 95% CI 1.29-3) [24]. Further dose-adjusted observational 
human studies from Germany [25] and Scotland [26] have supported 
these findings, but not a database review from the United Kingdom 
[27] nor other manuscripts [19,28,29]. As these studies were 
observational, care needs to be exercised with interpretation. Thus 
although there is mechanistic data supporting mitogenicity of insulin 
glargine and observational human data suggesting an association with 
carcinogenicity, human clinical trial data to date have not shown clear 
evidence of an increased cancer risk.
Maternofetal Transport
Most data on risk of congenital malformations with the new 
insulins in pregnancy has come from observational data. So far the 
largest amount of data regarding pregnancy outcomes for any insulin 
analogue is for insulin lispro. Reassuringly several retrospective studies 
have shown no clear association between the use of this analogue as 
compared to regular insulin [30]. 
Similar data on outcomes are not available for insulin glulisine 
(which is FDA pregnancy category C) or insulin glargine. A prospective 
study of Aspart in 322 subjects with Type 1 diabetes during pregnancy 
has not raised any safety concerns [31]. The results of a prospective 
study of detemir in pregnancy is awaited. However as the increased 
incidence or malformations above baseline diabetic risk is small, 
much larger exposures will be necessary to study the question. Due to 
the strong affinity for IGF-1–receptor binding with glargine and the 
mitogenic potential discussed above, there are theoretical toxicological 
concerns with using glargine in pregnancy [32].
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Hypoglycaemia
There has been increased concern recently about hypoglycaemia, 
with evidence that this event could increase morbidity, mortality 
[33] and cognitive impairment [34]. There are also concerns with 
hypoglycaemic risk in pregnancy. As the insulin analogues glargine 
and detemir display a flatter pharmacokinetic profile suggesting a 
clinically significant reduction in hypoglycaemia incidence compared 
with NPH insulin, most studies have only shown a small reduction in 
nocturnal hypoglycaemic incidence leaving the “fear of hypoglycaemia 
to remain. A recent study in patients with type 1 diabetes mellitus 
with severe hypoglycaemia on NPH who were changed to glargine 
or detemir still experienced severe hypoglycaemia and few patients 
reached internationally accepted glycaemic treatment goals [35]. In fact 
a Cochrane review article showed no glycaemic benefit of long-acting 
insulin analogues compared with intermediate-acting insulin [36].
Clinical Effectiveness
In T1D, there is some evidence that glargine is more effective 
than NPH in reducing FBG, and other evidence that shows they are 
the same. Both have the same effect on HBA1c. To date there has not 
been reported any well conducted studies that show a difference in 
clinical outcome between NPH and the newer insulins. The number 
of episodes of hypoglycaemia may be slightly less with glargine but the 
clinical relevance of this is unknown.  Further this effect was seen when 
glargine was compared with once daily and not twice daily NPH. An 
‘older’ review of the literature is documented  in the Health Technology 
Assessment systematic reviews, summarized in [37]. In a more recent 
systematic review of randomised controlled trials, there was a clinically 
non significant difference between rapid-acting insulin analogues and 
RHI in adults with both T1D and T2D. Similarly, differences between 
long-acting insulin analogues and NPH insulin in terms of HbA1c were 
marginal among adults with either T1D or T2D. Benefits in terms 
of reduced hypoglycemia were inconsistent. Similarly to the earlier 
systematic reviews there was insufficient data to have any certainty as 
to whether insulin analogues are better than conventional insulins in 
reducing long-term diabetes-related complications or death [38]. To 
date, the lack of long-term and good quality studies means we can only 
suggest that rapid-and long-acting insulin analogues appear to offer 
little comparative benefit relative to conventional insulins in terms 
of glycemic control or reduced hypoglycemia;  and that comparative 
efficacy on reductions in long-term complications of diabetes is 
unknown.
Premixed Insulins
Similarly, evidence from clinical trials on clinical outcome with 
premixed insulins is inconclusive. A systematic review of surrogate 
endpoints has found that premixed insulin analogues provide glycemic 
control similar to that of premixed human insulin. Premixed analogues 
may provide slightly tighter glycemic control than long-acting insulin 
analogues. Specifically premixed insulin analogues were similar to 
premixed human insulin in decreasing FBG, HbA1c and the incidence 
of hypoglycemia. They were slightly more effective in decreasing 
postprandial glucose levels (mean difference −1.1 mmol/L; 95% CI, 
−1.4 to −0.7 mmol/L) . Compared with long-acting insulin analogues, 
premixed insulin analogues were superior in decreasing postprandial 
glucose levels (mean difference, −1.5 mmol/L; CI, −1.9 to −1.2 
mmol/L) and HbA1c (mean difference, −0.39% [CI, −0.50% to −0.28%]) 
but were inferior in decreasing fasting glucose levels (mean difference, 
0.7 mmol/L; CI, 0.3 to 1.0 mmol/L) and were associated with a higher 
incidence of hypoglycemia [39]. 
Other Issues
Continuous subcutaneous insulin infusions (CSII) have been used 
to treat diabetes since the 1970s with efficacy data comparable to that 
of multiple daily insulin regimes, particularly in adults with Type 1 
diabetes. CSII therapy is designed to provide both rapid insulin action 
to cover meal-time requirements and variable basal insulin delivery. The 
development of rapid acting insulin analogues with uniform absorption 
characteristics has further assisted the effectiveness of CSII therapy, 
reducing the size of the subcutaneous insulin depot and shortening 
the time interval between insulin administration and action. Recently 
the option of linked subcutaneous sensor capacity has emerged in the 
new generation pumps, clinical trials are underway. Clinical studies 
have validated comparable HbA1c lowering effects of insulin aspart 
and lispro compared with regular insulin when the boluses of soluble 
insulin were administered 30 minutes prior to the meal, and better than 
regular insulin when aspart and lispro was administered immediately 
prior to the meal [40], however there is a risk of rapid development of 
ketoacidosis if there is an interruption in insulin delivery such as may 
occur in pump failure or catheter occlusion.
The Future
The experience of Exubera® led most companies who were 
developing inhaled insulin to cease their programmes. An exception 
has been MannKind who have developed a small device utilising 
technosphere technology which allows delivery and absorption of 
insulin very rapidly to the circulation and with small but reversible 
changes in pulmonary function [41]. Oral insulin continues to be 
pursued as does further research into the development of ultra-long-
acting insulins such as pegylated insulins that only need administration 
every few days. Other novel concepts include “SmartInsulin” which 
releases insulin in a glucose dependent manner [42].
Summary
There have been major advances in insulin therapy over the last 
50 years. It is noteworthy that although both inhalational and buccal 
technologies have been developed, clinical and delivery problems with 
the use of these technologies remain. Further developments including 
islet and gene replacement are exciting, but in the meantime we must 
work with subcutaneous administration of insulins for the majority 
of people, and work to streamline the approach of using appropriate 
insulins for the individual patient.
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